On the other hand, due to the limited number of patients treated with PD-1/PD-L1 inhibitor, further large-scale prospective studies are required to validate the results and examine the clinical utility of mRECIST in advanced HCC patients. The gene discussed is PDCD1; the disease is hepatocellular carcinoma.